Transaction DateRecipientSharesTypePriceValue
17th July 2020Robert Janssen50,000Open or private sale$11.09$554,500.00
27th May 2020Andrew A. F. Hack1,000,000Open or private purchase$5.00$5,000,000.00
19th May 2020Robert Janssen15,000Open or private sale$6.33$94,950.00
6th May 2020Robert Janssen28,000Open or private sale$4.52$126,560.00
5th May 2020Robert Janssen9,000Open or private sale$4.43$39,870.00
7th April 2020Andrew A. F. Hack2,800,000Open or private purchase$5.59$15,652,000.00
7th April 2020Andrew A. F. Hack645,667Open or private purchase$7.74$4,997,462.58
16th March 2020Michael S Ostrach12,684Payment by withholding$2.32$29,426.88
16th March 2020Michael S Ostrach4,901Payment by withholding$2.32$11,370.32
16th March 2020Michael S Ostrach27,352Payment by withholding$2.32$63,456.64
Dynavax Technologies
Dynavax Technologies logo

Dynavax Technologies Corp. is a biopharmaceutical company. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996.

Ticker: DVAX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1029142
Employees: 231
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $38 M (0%)
Inventory, Net: $48 M (0%)
Assets, Current: $194 M (-6%)
Property, Plant and Equipment, Net: $31 M (-3%)
Other Assets, Noncurrent: $3 M (-1%)
Assets: $259 M (-7%)
Accounts Payable, Current: $5 M (-50%)
Accrued Liabilities, Current: $12 M (-17%)
Liabilities, Current: $29 M (-44%)
Long-term Debt, Excluding Current Maturities: $180 M (0%)
Other Liabilities, Noncurrent: $2 M (24%)
Liabilities: $247 M (-8%)
Common Stock, Value, Issued: $88 Th (4%)
Common Stock, Shares, Issued: $88 Th (4%)
Additional Paid in Capital, Common Stock: $1 B (1%)
Retained Earnings (Accumulated Deficit): $1 B (1%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $3 M (7%)
Stockholders' Equity (Parent): $12 M (0%)
Liabilities and Equity: $259 M (-7%)
Revenue: $11 M (89%)
Research and Development: $5 M (-78%)
Operating Income/Loss: $19 M (-48%)
EPS (basic): $0.15 (-75%)
EPS (diluted): $0.25 (-59%)